ZYME - Zymeworks Inc.
Zymeworks Inc. , a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
As of May 15, 2026: spot at $23.70, ATM IV 43.7%, max pain $22.50, net GEX $24.4K.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $1.81B
- Beta
- 1.19
- 52-Week Range
- 10.93-29.75
- CEO
- Kenneth H. Galbraith
- Employees
- 299
- IPO Date
- Apr 28, 2017
- Exchange
- NASDAQ
What ZYME Looks Like to Options Traders Today
IV rank of 2.6% is subdued relative to the 1-year history, conditions that typically favor premium-buying or long-volatility structures (debit spreads, calendar spreads, long straddles); positive net gamma exposure ($24.4K) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (0.173) prices calls richer than puts, often reflecting upside speculation or squeeze risk.
What This Page Covers
The ZYME overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked ZYME overview questions
- What is ZYME?
- ZYME is the ticker symbol for Zymeworks Inc., a listed security. Zymeworks Inc. , a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. Listed on NASDAQ. ZYME is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the ZYME options snapshot look like today?
- As of May 15, 2026, the ZYME options snapshot shows spot at $23.70, ATM IV 43.7%, IV rank 2.6%, max pain $22.50, net GEX $24.4K, expected move 12.53%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are ZYME's key statistics?
- Zymeworks Inc. (ZYME) carries a market capitalization of $1.81B, beta of 1.19 relative to the broader market, 52-week range of 10.93-29.75. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does ZYME belong to?
- Zymeworks Inc. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare ZYME's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the ZYME data on this page?
- The options snapshot above is dated May 15, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).